$159.37
+3.17
(+2.03%)▲
2.18%
Downside
Day's Volatility :2.81%
Upside
0.64%
22.8%
Downside
52 Weeks Volatility :23.55%
Upside
0.98%
Period | Quest Diagnostics Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 5.95% | 0.1% | 12.2% |
6 Months | 13.21% | 4.6% | 14.8% |
1 Year | 20.42% | 18.9% | 35.8% |
3 Years | 7.51% | 12.8% | 29.0% |
Market Capitalization | 17.4B |
Book Value | $60.80 |
Dividend Share | 2.96 |
Dividend Yield | 1.93% |
Earnings Per Share (EPS) | 7.48 |
PE Ratio | 20.88 |
PEG Ratio | 1.81 |
Wall Street Target Price | 168.85 |
Profit Margin | 8.82% |
Operating Margin TTM | 14.19% |
Return On Assets TTM | 5.66% |
Return On Equity TTM | 13.22% |
Revenue TTM | 9.5B |
Revenue Per Share TTM | 85.74 |
Quarterly Revenue Growth YOY | 8.4% |
Gross Profit TTM | 3.5B |
EBITDA | 1.8B |
Diluted Eps TTM | 7.48 |
Quarterly Earnings Growth YOY | 0.02 |
EPS Estimate Current Year | 8.9 |
EPS Estimate Next Year | 9.76 |
EPS Estimate Current Quarter | 2.26 |
EPS Estimate Next Quarter | 2.22 |
What analysts predicted
Upside of 5.95%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.5B | ↓ 2.31% |
Net Income | 736.0M | ↓ 4.66% |
Net Profit Margin | 9.77% | ↓ 0.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.7B | ↑ 2.59% |
Net Income | 858.0M | ↑ 16.58% |
Net Profit Margin | 11.11% | ↑ 1.34% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 9.4B | ↑ 22.15% |
Net Income | 1.4B | ↑ 66.78% |
Net Profit Margin | 15.16% | ↑ 4.05% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 10.8B | ↑ 14.32% |
Net Income | 2.0B | ↑ 39.41% |
Net Profit Margin | 18.49% | ↑ 3.33% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 9.9B | ↓ 8.39% |
Net Income | 946.0M | ↓ 52.58% |
Net Profit Margin | 9.57% | ↓ 8.92% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 9.3B | ↓ 6.38% |
Net Income | 854.0M | ↓ 9.73% |
Net Profit Margin | 9.23% | ↓ 0.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.3B | ↑ 0.3% |
Net Income | 235.0M | ↑ 16.34% |
Net Profit Margin | 10.05% | ↑ 1.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.3B | ↓ 1.84% |
Net Income | 225.0M | ↓ 4.26% |
Net Profit Margin | 9.8% | ↓ 0.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.3B | ↓ 0.31% |
Net Income | 192.0M | ↓ 14.67% |
Net Profit Margin | 8.39% | ↓ 1.41% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 3.41% |
Net Income | 194.0M | ↑ 1.04% |
Net Profit Margin | 8.2% | ↓ 0.19% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 1.31% |
Net Income | 229.0M | ↑ 18.04% |
Net Profit Margin | 9.55% | ↑ 1.35% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↑ 3.8% |
Net Income | 226.0M | ↓ 1.31% |
Net Profit Margin | 9.08% | ↓ 0.47% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 11.0B | ↑ 4.76% |
Total Liabilities | 5.7B | ↑ 3.49% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 12.8B | ↑ 16.72% |
Total Liabilities | 7.1B | ↑ 25.11% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 14.0B | ↑ 9.21% |
Total Liabilities | 7.1B | ↑ 0.78% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.6B | ↓ 2.96% |
Total Liabilities | 7.0B | ↓ 1.21% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 12.8B | ↓ 5.69% |
Total Liabilities | 6.8B | ↓ 3.11% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 14.0B | ↑ 9.23% |
Total Liabilities | 7.6B | ↑ 11.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.4B | ↑ 4.93% |
Total Liabilities | 7.1B | ↑ 6.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.5B | ↑ 0.42% |
Total Liabilities | 6.9B | ↓ 1.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.0B | ↑ 4.01% |
Total Liabilities | 7.6B | ↑ 9.52% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 14.0B | ↓ 0.48% |
Total Liabilities | 7.4B | ↓ 2.58% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 13.9B | ↓ 0.52% |
Total Liabilities | 7.1B | ↓ 3.54% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 16.1B | ↑ 15.95% |
Total Liabilities | 9.2B | ↑ 28.38% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↑ 2.13% |
Investing Cash Flow | -801.0M | ↓ 0.5% |
Financing Cash Flow | -401.0M | ↓ 32.26% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↑ 3.58% |
Investing Cash Flow | -411.0M | ↓ 48.69% |
Financing Cash Flow | 225.0M | ↓ 156.11% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↑ 61.3% |
Investing Cash Flow | -772.0M | ↑ 87.83% |
Financing Cash Flow | -1.3B | ↓ 663.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↑ 11.37% |
Investing Cash Flow | 21.0M | ↓ 102.72% |
Financing Cash Flow | -2.5B | ↑ 100.47% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↓ 23.06% |
Investing Cash Flow | -543.0M | ↓ 2685.71% |
Financing Cash Flow | -1.7B | ↓ 31.81% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 444.0M | ↑ 372.34% |
Investing Cash Flow | -840.0M | ↑ 431.65% |
Financing Cash Flow | 189.0M | ↓ 348.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 207.0M | ↓ 53.38% |
Investing Cash Flow | -947.0M | ↑ 12.74% |
Financing Cash Flow | -83.0M | ↓ 143.92% |
Sell
Neutral
Buy
Quest Diagnostics Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Quest Diagnostics Inc. | 7.2% | 13.21% | 20.42% | 7.51% | 58.07% |
Idexx Laboratories, Inc. | -9.03% | -13.86% | 0.21% | -29.55% | 71.47% |
Agilent Technologies Inc. | -4.96% | -7.5% | 27.19% | -13.92% | 77.85% |
Thermo Fisher Scientific, Inc. | -7.57% | -6.6% | 23.94% | -12.63% | 87.97% |
Danaher Corp. | -9.23% | -2.47% | 25.21% | -19.42% | 82.42% |
Iqvia Holdings Inc. | -4.37% | -4.28% | 13.2% | -13.2% | 56.01% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Quest Diagnostics Inc. | 20.88 | 20.88 | 1.81 | 8.9 | 0.13 | 0.06 | 0.02 | 60.8 |
Idexx Laboratories, Inc. | 40.81 | 40.81 | 4.46 | 10.56 | 0.59 | 0.23 | NA | 19.72 |
Agilent Technologies Inc. | 29.03 | 29.03 | 2.97 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Thermo Fisher Scientific, Inc. | 35.09 | 35.09 | 2.13 | 21.69 | 0.13 | 0.05 | 0.0 | 128.08 |
Danaher Corp. | 46.52 | 46.52 | 2.89 | 7.5 | 0.08 | 0.04 | 0.0 | 71.03 |
Iqvia Holdings Inc. | 28.58 | 28.58 | 1.14 | 11.14 | 0.22 | 0.05 | NA | 38.37 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Quest Diagnostics Inc. | Hold | $17.4B | 58.07% | 20.88 | 8.82% |
Idexx Laboratories, Inc. | Buy | $35.5B | 71.47% | 40.81 | 22.53% |
Agilent Technologies Inc. | Buy | $40.1B | 77.85% | 29.03 | 21.75% |
Thermo Fisher Scientific, Inc. | Buy | $214.1B | 87.97% | 35.09 | 14.48% |
Danaher Corp. | Buy | $177.8B | 82.42% | 46.52 | 16.39% |
Iqvia Holdings Inc. | Buy | $39.8B | 56.01% | 28.58 | 9.17% |
Insights on Quest Diagnostics Inc.
Revenue is up for the last 4 quarters, 2.28B → 2.48B (in $), with an average increase of 2.8% per quarter
Netprofit is down for the last 2 quarters, 229.0M → 226.0M (in $), with an average decrease of 1.3% per quarter
In the last 1 year, Agilent Technologies Inc. has given 26.0% return, outperforming this stock by 6.0%
Vanguard Group Inc
BlackRock Inc
State Street Corp
Victory Capital Management Inc.
Morgan Stanley - Brokerage Accounts
American Century Companies Inc
In the quarter ending March,2024. Quest Diagnostics Inc. has declared dividend of $0.71
Read Morequest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Organization | Quest Diagnostics Inc. |
Employees | 50000 |
CEO | Mr. James E. Davis |
Industry | Health Services |
Iqvia Holdings Inc.
$159.37
+2.03%
Williams-sonoma Inc.
$159.37
+2.03%
Lpl Financial Holdings Inc.
$159.37
+2.03%
Fair Isaac Corp
$159.37
+2.03%
Affirm Holdings Inc
$159.37
+2.03%
Exelon Corporation
$159.37
+2.03%
Royalty Pharma Plc
$159.37
+2.03%
Performance Food Group Company
$159.37
+2.03%
S&p 500 Value Index Ishares
$159.37
+2.03%